Disabling inflammatory pathways with biologics and resulting clinical outcomes in severe asthma

Expert Opinion on Biological Therapy

Volumn 13, Issue 3, 2013, Pages 393-402

  Caruso, Massimo ^a   Crisafulli, Emanuele ^a   Demma, Shirin ^a   Holgate, Stephen ^b   Polosa, Riccardo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Biologics; Immunopharmacology; Inflammatory pathways; Monoclonal antibodies; Severe asthma

Indexed keywords

ALTRAKINCEPT; ANRUKINZUMAB; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; BECLOMETASONE; BENRALIZUMAB; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL PRODUCT; BRODALUMAB; BRONCHODILATING AGENT; CINQUIL; CORTICOSTEROID; CYT 003QBG 10; DACLIZUMAB; GOLIMUMAB; IMA 026; IMMUNOGLOBULIN E; INFLIXIMAB; KELIXIMAB; LEBRIKIZUMAB; MEPOLIZUMAB; MONOCLONAL ANTIBODY; OMALIZUMAB; PASCOLIZUMAB; QAX 576; RESLIZUMAB; RG 7449; SECUKINUMAB; TRALOKINUMAB; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ASTHMA; DRUG EFFICACY; DRUG ERUPTION; DRUG TARGETING; EOSINOPHILIA; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; NAUSEA; NOSE OBSTRUCTION; OUTCOME ASSESSMENT; RESPIRATORY TRACT INFLAMMATION; REVIEW; RHINOPHARYNGITIS; T LYMPHOCYTE; TARGET CELL; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL AGENTS; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84873889401     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.743989     Document Type: Review

References (88)

1. BTS/SIGN British Guideline on Management of Asthma. British Thoracic Society Scottish Intercollegiate Guidelines network. Thorax 2008;63(Suppl 4):iv1-121
2. Polosa R. An overview of chronic severe asthma. Intern Med J 2008;38(3):190-8
3. Smith DH, Malone DC, Lawson KA, et al. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997;156(3 Pt 1):787-93
4. Godard P, Chanez P, Siraudin L, et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Respir J 2002;19(1):61-7
5. Antoncelli L, Bucca C, Neri M, et al. Asthma severity and medical resource utilization. Eur Respir J 2004;23:723-9
6. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006;Aug 26;368(9537):780-93
7. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med 2010;Feb 15;181(4):315-23
8. Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011;Feb 12;7(2):355-60
9. Chanez P, Wenzel SE, Anderson GP, et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol 2007;119(6):1337-48
10. Polosa R, Benfatto GT. Managing patients with chronic severe asthma: rise to the challenge. Eur J Intern Med 2009;Mar 20(2):114-24
11. Currie GP, Douglas JG, Heaney LG. Difficult to treat asthma in adults. BMJ 2009;338:b494
12. Morjaria JB, Polosa R. Recommendation for optimal management of severe refractory asthma. Journal of Asthma and Allergy 2010;3:43-56
13. Robinson D, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326(5):298-304
14. Cazzola M, Polosa R. Anti-TNF-alfa and Th1 cytokine-directed therapies for the treatment of asthma. Curr Opin Allergy Clin Immunol 2006;Feb6(1):43-50
15. Thorburn A, Hansbro P. Harnessing Regulatory T cells to Suppress Asthma: from Potential to Therapy. Am J Respir Cell Mol Biol 2010;43(5):511-19
16. Di Domenico M, Bisogno A, Polverino M, et al. Xolair in asthma therapy: an overview. Inflamm Allergy Drug Targets 2011;10:2-12
17. Demeule B, Shire SJ, Liu J, et al. A therapeutic antibody and its antigen form different complexes in serum than in phosphate-buffered saline: a study by analytical ultracentrifugation. Anal Biochem 2009;388:279-87
18. Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 2004;114:527-30
19. Schroeder JT, Bieneman AP, Chichester KL, et al. Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol 2010;125:896-901
20. Patou J, Gevaert P, Van Zele T, et al. Staphylococcus aureus enterotoxin B, protein A, and lipoteichoic acid stimulations in nasal polyps. J Allergy Clin Immunol 2008;121(1):110-15
21. Morjaria JB, Polosa R. Off-label use of omalizumab in non-asthma conditions: new opportunities. Expert Rev Resp Med 2009;3(3):299-308
22. Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006(2):CD003559
23. Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009;124(6):1210-16
24. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2009. Available from: http://www.ginasthma.org
25. Domingo C, Moreno A, Jose Amengual M, et al. Omalizumab in the management of oral corticosteroid-dependent IGE-mediated asthma patients. Curr Med Res Opin 2011;27(1):45-53
26. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007;101:1483-92
27. Zaidi AK, Saini SS, Macglashan DW Jr. Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab. J Allergy Clin Immunol 2010;125(4):902-8
28. Schumann C, Kropf C, Wibmer T, et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J 2011; Epub ahead of print
29. http://www.gene.com/gene/pipeline/status/immunology/anti-m1/index.html
30. Rosenwasser LJ, Busse WW, Lizambri RG, et al. Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. J Allergy Clin Immunol 2003;112(3):563-70
31. Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol 2006;24:147-74
32. Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160:1001-8
33. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112(7):1029-36
34. Tanaka H, Komai M, Nagao K, et al. Role of interleukin-5 and eosinophils in allergen-induced airway remodeling in mice. Am J Respir Cell Mol Biol 2004;31(1):62-8
35. Molfino NA, Gossage D, Kolbeck R, et al. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 2011; [Epub ahead of print]
36. Foster PS, Hogan SP, Yang M, et al. Interleukin-5 and eosinophils as therapeutic targets for asthma. Trends Mol Med 2002;8:162-7
37. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176(11):1062-71
38. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167(2):199-204
39. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356(9248):2144-8
40. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360(10):985-93
41. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360(10):973-84
42. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9
43. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003;167:1655-9
44. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184:1125-32
45. Busse WW, Katial R, Gossage D, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010;125(6):1237-44
46. Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998;282:2258-61
47. Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010;19(115):46-54
48. Hart P, Bonder C, Balogh J, et al. Differential responses of human monocytes and macrophages to IL-4 and IL-13. J Leukoc Biol 1999;66(4):575-8
49. Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003;111(4):677-90
50. Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo controlled trial. Am J Respir Crit Care Med 1999;160:1816-23
51. Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001;107:963-70
52. Hart TK, Blackburn MN, Brigham-Burke M, et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized antiinterleukin-4 antibody with therapeutic potential in asthma. Clin Exp Immunol 2002;130:93-100
53. Gauvreau GM, Boulet LP, Fitzgerald JM, et al. The effects of IMA-638 on allergen induced airway responses in subjects with mild atopic asthma. Eur Respir J 2008;32(Suppl):52-827s
54. Gauvreau GM, Boulet L-P, Cockcroft DW, et al. Effects of Interleukin-13 Blockade on Allergen-induced Airway Responses in Mild Atopic Asthma. Am J Respir Crit Care Med 2011;183:1007-14
55. Kasaian MT, Raible D, Marquette K, et al. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Ralpha2. J Immunol 2011;187:561-9
56. Kariyawasam HH, Nicholson GC, Tan AJ, et al. Effects of anti-IL-13 (Novartis QAX576) on inflammatory responses following nasal allergen challenge (NAC). Am J Respir Crit Care Med 2009;179:A3642
57. Singh D, Kane B, Molfino NA, et al. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm Med 2010;10:3
58. http://clinicaltrials.gov/ct2/show/NCT00873860
59. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-98
60. Fitch N, Morton M, Bowden A, et al. Preclinical evaluation of BAY 16-9996 a dual IL-4/IL-13 receptor antagonist. J Allergy Clin Immunol 2001;107(Suppl):S331-9
61. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370(9596):1422-31
62. http://clinicaltrials.gov/ct2/show/NCT00801853?term=Aerovant+AND +asthma&rank=1
63. Hodges MR, Castelloe E, Chen A, et al. Randomized, double-blind, placebo controlled first in human study of inhaled AIR645, an IL-4Ralpha oligonucleotide, in healthy volunteers. Am J Respir Crit Care Med 2009;179:A3640
64. Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG317, an IL-4Ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010;181(8):788-96
65. Russo C, Polosa R. TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin Sci (Lond) 2005;109(2):135-42
66. Morjaria JB, Malerba M, Polosa R. Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD. Drug Discov Today 2010;15:396-405
67. Van Bogaert T, De Bosscher K, Libert C, et al. Crosstalk between TNF and glucocorticoid receptor signaling pathways. Cytokine & Growth Factor Reviews 2010;21:275-86
68. Howarth PH, Babu KS, Arshad HS, et al. Tumour Necrosis Factor (TNF) alpha as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax 2005;60:1012-18
69. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006;354(7):697-708
70. Morjaria JB, Polosa R, Holgate ST, et al. The role of a soluble TNF-alpha receptor fusion protein (Etanercept) in corticosteroid-refractory asthma: a double blind, randomised placebo controlled trial. Thorax 2008;63(7):584-91
71. Holgate ST, Noonan M, Chanez P, et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J 2011;37:1352-9
72. Erin E, Leaker B, Nicholson G, et al. The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006;174(7):753-62
73. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179(7):549-58
74. Kon OM, Sihra BS, Loh LC, et al. The effects of an anti-CD4 monoclonal antibody, keliximab, on peripheral blood CD4+ Tcells in asthma. Eur Respir J 2001;18(1):45-52
75. Kon OM, Sihra BS, Compton CH, et al. Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma. Lancet 1998;352(9134):1109-13
76. Azzawi M, Johnston PW, Majumdar S, et al. T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis. Am Rev Respir Dis 1992;145(6):1477-82
77. Busse WW, Israel E, Nelson HS, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med 2008;178(10):1002-8
78. Oh CK, Raible D, Geba G, et al. Biology of IL-9 pathway and its therapeutic potential for the treatment of asthma. Inflamm. Allergy Drug Targets 2011;10:180-6
79. http://clinicaltrials.gov/ct2/show/NCT00968669
80. Parker J, Brazinsky S, Miller DS, et al. Randomized, double-blind, placebo-controlled, multicenter Phase 2A study to evaluate the effect of a humanized IL-9 monoclonal antibody (MEDI-528) on exercise-induced bronchospasm. Am J Respir Crit Care Med 2010;181:5394
81. Wang YH, Liu YJ. OX40-OX40L interactions: a promising therapeutic target for allergic diseases? J Clin Invest 2007;117:3655-7
82. Hoshino A, Tanaka Y, Akiba H, et al. Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma. Eur J Immunol 2003;33:861-9
83. http://clinicaltrials.gov/ct2/show/NCT00983658
84. Aggarwal S, Gurney AL. IL-17: prototype member of an emerging cytokine family. J Leukoc Biol 2002;71(1):1-8
85. http://clinicaltrials.gov/ct2/show/NCT01199289?term=AMG827+AND +asthma&rank=1
86. http://clinicaltrials.gov/ct2/show/NCT01478360?term=AIN457+AND +asthma&rank=1
87. Gauvreau GM, Hessel EM, Boulet L, et al. Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med 2006;174:15-20
88. Cytos. Placebo-controlled phase II study shows CYT003-QbG10 is safe and efficacious for the treatment of allergic asthma. 2010. Available from: http://www.cytos.com/userfiles/file/Cytos-Press-E-100521.pdf